View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Pfizer to halt new clinical trial initiations in Russia amid Ukraine crisis

In an analysis by Clinical Trials Arena, Pfizer ranks ninth in the top 10 pharma companies with an ongoing and planned Phase I-III trial in Russia.

Understand the impact of the Ukraine conflict from a cross-sector perspective with the Global Data Executive Briefing: Ukraine Conflict

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Pfizer has announced that the company will not commence any new clinical trials in Russia amid the Ukraine crisis. The company will also halt participant recruitment in trials that are underway in Russia. 

Working with the Food and Drug Administration (FDA) and other regulatory agencies, Pfizer will transition all trials underway to various other study centres outside of the country. 

Furthermore, the company will offer the required drugs to the patients who are currently enrolled in trials, as part of its commitment to prioritise patients.

Previously, Clinical Trials Arena reported on 2 March that one of Russia’s top recruiting clinical trial sites paused recruitment of new patients in studies sponsored by overseas companies. We also did an analysis on how many clinical trials are at risk in Ukraine (24 February) and in Russia (7 March). In our Russia analysis, Pfizer ranks ninth in the top 10 pharma companies with an ongoing or planned Phase I-III trial in Russia.

Pfizer does not own or manage any manufacturing sites in Russia, thus all potential investments with suppliers in the country to expand manufacturing capacity will be halted by the company.

The company concluded that a voluntary halt in medicine flow to Russia would violate its foundational principle of putting patients first. 

Talking about the humanitarian supply of therapies to Russia, Pfizer said in a press statement: “As with all previous instances, for humanitarian reasons, medicines were excluded from these sanctions. 

“Ending delivery of medicines, including cancer or cardiovascular therapies, would cause significant patient suffering and potential loss of life, particularly among children and elderly people.”

Continuing the delivery of treatments to Russia however does not imply that the company will carry out business as normal in the country, Pfizer added.

In addition, all the profits of the company’s subsidiary in Russia will be donated to causes that offer humanitarian support to Ukrainians. 

This donation is apart from Pfizer’s already announced commitments to Ukraine.

The latest development comes after the company’s CEO Albert Bourla told CBS News that it has no intention to make additional investments in Russia amid the Ukraine crisis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena